
Major Depressive Disorder (MDD) is a serious, mental health condition that goes far beyond ordinary sadness. If you or someone you care about is struggling with depression, our providers are here to help guide you toward lasting relief and a better quality of life.
Major Depressive Disorder (MDD) is a serious and pervasive mental health condition characterized by persistent feelings of sadness, emptiness, or hopelessness — along with a loss of interest or pleasure in activities once enjoyed. Unlike temporary feelings of sadness, MDD causes profound disruptions in thinking, sleep, appetite, energy, and the ability to function at work, in relationships, and in daily life.
According to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), a diagnosis of MDD requires the presence of five or more specific symptoms during the same two-week period, with at least one symptom being depressed mood or loss of interest — and these symptoms must represent a change from previous functioning and cause clinically significant distress or impairment.
MDD is one of the most common mental health conditions globally and is among the leading causes of disability worldwide. It affects people of all ages, backgrounds, and walks of life — and it is highly treatable.
Adults in the U.S. experience at least one major depressive episode annually
Source: NIMH, 2023
Of those with MDD see significant improvement with treatment
Early intervention is key to achieving remission and preventing recurrence
MDD does not have a single cause. It arises from a complex interplay of biological, psychological, and environmental factors. Neurobiological research points to dysregulation of key neurotransmitter systems — including serotonin, norepinephrine, and dopamine — as central to the disorder's pathophysiology. Structural and functional brain changes, particularly in the prefrontal cortex, amygdala, and hippocampus, are also observed in individuals with MDD.
Symptoms vary in severity and presentation but must persist for at least two weeks to meet diagnostic criteria:
Feelings of sadness, emptiness, or hopelessness nearly every day
Markedly diminished interest or pleasure in all or most activities
Persistent tiredness and loss of energy, even without physical exertion
Insomnia or hypersomnia; difficulty initiating or maintaining sleep
Difficulty concentrating, remembering details, or making decisions
Significant weight loss or gain, or changes in appetite nearly every day
Observable agitation or slowing in movement and speech
Excessive guilt, self-blame, or feelings of being a burden to others
Recurrent thoughts of death, self-harm, or suicidal ideation or attempts
MDD is a multifactorial disorder. No single factor determines whether a person will develop it, but a combination of the following elements can substantially increase risk:
MDD is one of the most treatable psychiatric conditions. A combination of approaches — tailored to the individual — yields the best outcomes. Treatment typically involves medication, therapy, or both, along with lifestyle modifications and social support.
Below are the main treatment modalities used in the management of MDD:
SSRIs, SNRIs, TCAs, MAOIs, and atypical agents targeting brain neurochemistry
CBT, interpersonal therapy, and behavioral activation provided by licensed counselors
TMS (transcranial magnetic stimulation) or ECT for severe or treatment-resistant cases
Regular exercise, structured sleep, nutrition, and stress management techniques
Support groups, community resources, and building resilient social networks
Combining medications or adding mood stabilizers or antipsychotics when needed
Medivira provides medication management only. We do not offer therapy or counseling services directly. However, we firmly believe that comprehensive care leads to the best outcomes — which is why we refer our patients to our trusted network of licensed counselors and therapists. Our providers work collaboratively alongside your therapist to ensure your treatment is fully coordinated and optimized.
Clinical Evidence: A landmark study published in the American Journal of Psychiatry demonstrated that SSRIs produce statistically significant reductions in depressive symptom severity compared to placebo, with response rates of 40–60% in patients with MDD and a favorable long-term safety profile supporting their role as a first-line pharmacological treatment.
Cipriani A, et al. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder. The American Journal of Psychiatry.
🔗 View study on American Journal of PsychiatryTreatment-resistant depression is generally defined as MDD that fails to respond adequately to at least two different antidepressant medications at appropriate doses and durations. TRD affects an estimated 10–30% of individuals with MDD and represents a significant clinical challenge. Management options for TRD include medication augmentation strategies (adding lithium, atypical antipsychotics, or thyroid hormone), switching medication classes, ketamine or esketamine (Spravato) infusion therapy, electroconvulsive therapy (ECT), and repetitive transcranial magnetic stimulation (rTMS). If you have tried multiple antidepressants without adequate relief, our providers can conduct a comprehensive medication review to explore advanced treatment pathways tailored to your needs.
Selecting the right medication for MDD is a nuanced, individualized process. At Medivira, our psychiatric providers conduct thorough evaluations to identify the safest and most effective medication strategy for each patient, considering prior medication history, comorbidities, potential drug interactions, and patient preferences.
Many people delay seeking care for depression, attributing their symptoms to stress, personality, or circumstance. Recognizing when professional help is needed is a critical first step. You should consider reaching out to a healthcare provider if you experience:
If you are experiencing thoughts of self-harm or suicide, call or text 988 (Suicide & Crisis Lifeline) immediately, or go to your nearest emergency room. You are not alone, and help is available right now.
Here are answers to the questions our patients most commonly ask about Major Depressive Disorder and medication management at Medivira.
MDD is diagnosed through a clinical evaluation conducted by a licensed mental health or medical provider. Diagnosis is based on DSM-5 criteria, requiring the presence of five or more depressive symptoms for at least two weeks, with at least one being depressed mood or loss of interest/pleasure. Your provider will also rule out medical conditions or medications that could cause similar symptoms. There is no lab test for depression — diagnosis is clinical.
MDD is highly treatable, and many individuals achieve full remission — meaning no significant symptoms. However, MDD can be recurrent, with some patients experiencing multiple episodes over their lifetime. Long-term medication management and therapy can significantly reduce relapse risk. The goal of treatment is not just symptom reduction but sustained functional improvement and quality of life.
Most antidepressants take 4 to 8 weeks to produce full therapeutic effects, though some patients notice early improvements in sleep and energy within the first 1–2 weeks. It is important not to discontinue medication prematurely. If there is no meaningful response after an adequate trial, your Medivira provider will work with you to adjust the dose or explore alternative medications.
SSRIs (e.g., sertraline, escitalopram, fluoxetine) and SNRIs (e.g., venlafaxine, duloxetine) are the most commonly prescribed first-line agents due to their efficacy and tolerability. Atypical antidepressants such as bupropion and mirtazapine are also widely used. If a patient does not respond to initial treatments, augmentation agents or alternative medication classes may be introduced. The choice is individualized based on your symptom profile, history, and preferences.
Treatment-resistant depression (TRD) refers to MDD that has not responded adequately to at least two antidepressant trials of sufficient dose and duration. TRD requires specialized evaluation and may involve augmentation strategies, medication switches, esketamine therapy, TMS, or ECT. If you believe you may have TRD, Medivira's providers can perform a thorough medication review and develop a more targeted treatment plan.
Medivira specializes in medication management only — we do not provide therapy or counseling services. We recognize that therapy is a highly effective and often essential component of MDD treatment. To support comprehensive care, we refer our patients to our trusted network of licensed counselors and therapists, and we communicate closely with your therapist to ensure an integrated, coordinated approach to your mental health.
Getting started is simple. You can book an appointment directly through our online portal or by calling our office. At your initial visit, one of our psychiatric providers will conduct a comprehensive evaluation, review your medical and psychiatric history, and work collaboratively with you to develop a personalized medication management plan. We accept most major insurance plans — contact us to verify your coverage.
Expert medication management for Major Depressive Disorder — personalized, evidence-based, and compassionate. Book your appointment with Medivira today.
📅 Book Your AppointmentText or Call +1 (234) 567 89 00
Fax: 845-767-5049
Email : [email protected]
Address :
Medivira 400 Stonebrook Pkwy, STE 902 Frisco, TX 75036 Tel:+1469-888-8241
Last updated: March 2026
© 2026 All Rights Reserved.